|
Teva investing $500 million in the wound care market |
|
More info...
As part of the company's effort to expand into niche markets and to respond to mounting competition in the generic drug market as well as rivals to its first and most profitable original product, Copaxone, Teva Pharmaceutical Industries last week entered into nonbinding memoranda of understanding with Clal Biotechnology Industries subsidiaries MediWound (55% ) and Polyheal (41% ).
Hershey Medical Center researchers hope work with cells will revolutionize health care
Imagine you develop Parkinsons disease or leukemia, and all doctors have to do is culture your skin cells, tweak their genetic makeup, inject them into your body and they somehow, cure you.
|
No Comments.
